Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?

Gastroenterology

Volumn 153, Issue 4, 2017, Pages 890-892

  Maan, Raoel ^a   Feld, Jordan J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL THERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CHRONIC HEPATITIS C; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; EDITORIAL; FOLLOW UP; HAZARD RATIO; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; VIRAL CLEARANCE; HEPACIVIRUS; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 85032374198     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.08.052     Document Type: Editorial

References (17)

1. Backus, L.I., Boothroyd, D.B., Phillips, B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9 (2011), 509–516.e1.
2. van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
3. Davis, G.L., Alter, M.J., El-Serag, H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521.
4. Razavi, H., Waked, I., Sarrazin, C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 Suppl 1 (2014), 34–59.
5. Aleman, S., Rahbin, N., Weiland, O., et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57 (2013), 230–236.
6. El-Serag, H.B., Kanwal, F., Richardson, P., et al. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 64 (2016), 130–137.
7. van der Meer, A.J., Feld, J.J., Hofer, H., et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 66 (2017), 485–493.
8. Conti, F., Buonfiglioli, F., Scuteri, A., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
9. Ravi, S., Axley, P., Jones, D., et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 152 (2017), 911–912.
10. Reig, M., Marino, Z., Perello, C., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
11. Llovet, J.M., Villanueva, A., Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 13 (2016), 561–562.
12. Pol, S., Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 65 (2016), 734–740.
13. Kanwal, F., Kramer, J., Asch, S.M., et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153 (2017), 996–1005.
14. Romano, A., Capra, F., Piovessan, S., et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology, 2016.
15. Nagata, H., Nakagawa, M., Asahina, Y., et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol, 2017 Jun 13 [Epub ahead of print].
16. Nahon, P., Bourcier, V., Layese, R., et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156.
17. Cheung, M.C., Walker, A.J., Hudson, B.E., et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.